AB Science Announces Recruitment of First Patient in Phase 3 Study of Masitinib in Progressive Multiple Sclerosis
PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (NYSE-Euronext, FR0010557264, AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today recruitment of the first patient in the phase 3 study of masitinib in primary progressive multiple sclerosis or relapse free secondary progressive multiple sclerosis.